E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/11/2006 in the Prospect News Biotech Daily.

RBC upgrades Connetics to outperform

Connetics Corp. was upgraded to outperform from sector perform, speculative risk, by RBC Capital Markets analyst Ken Trbovich on news that the company's stock is oversold, representing an attractive buying opportunity for those willing to ride out uncertainty. Management is less-than-forthcoming in regards to accounting issues and the guidance, cautions the analyst. RBC estimates the equity value of Connetics at $340 million, or about $10 per share. Shares of the Palo Alto, Calif.-based pharmaceutical company were up 23 cents, or 2.96%, at $7.99 on volume of 3,033,472 shares versus the three-month running average of 706,122 shares. (Nasdaq: CNCT)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.